Journals / Turkish Journal of Surgery / 2017 / Cilt: 33 - Sayı: 3

Prognostic value of E2F1 in rectal cancer

Pages
180–184
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

When the patients were evaluated according to cytoplasmic staining with E2F transcription factor 1, the average overall survival rate of patients with positive E2F transcription factor 1 cytoplasmic staining was 48.0±4.6% versus 55.9±7.9% for patients without staining (p=0.408).Conclusion: The survival rates are higher in rectal cancer patients with strong immunohistochemical nuclear staining of E2F transcription factor 1.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To evaluate whether E2F transcription factor 1 is a potential prognostic marker in patients with rectal cancer.Material and Methods: Eighty-two patients who were treated with curative resection because of rectal cancer in the Erciyes University School of Medicine, Department of General Surgery were included in the study and analyzed retrospectively.
📊
Key Findings & Data:Nuclear and cytoplasmic staining of E2F transcription factor 1 was performed for immunohistochemical analysis on paraffinembedded and blocked tumor tissue samples of patients.
💡
Conclusion & Impact:When the patients were evaluated according to cytoplasmic staining with E2F transcription factor 1, the average overall survival rate of patients with positive E2F transcription factor 1 cytoplasmic staining was 48.0±4.6% versus 55.9±7.9% for patients without staining (p=0.408).Conclusion: The survival rates are higher in rectal cancer patients with strong immunohistochemical nuclear staining of E2F transcription factor 1.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To evaluate whether E2F transcription factor 1 is a potential prognostic marker in patients with rectal cancer.Material and Methods: Eighty-two patients who were treated with curative resection because of rectal cancer in the Erciyes University School of Medicine, Department of General Surgery were included in the study and analyzed retrospectively. Data were obtained from patient files, pathology reports, and hospital information system. Nuclear and cytoplasmic staining of E2F transcription factor 1 was performed for immunohistochemical analysis on paraffinembedded and blocked tumor tissue samples of patients. The findings of the study were assessed with using IBM Statistical Package for Social Sciences Statistics 20.Result: In the 5-year follow-up period, 34 (41.5%) patients were alive. Local recurrence was identified in 7 patients. According to E2F transcription factor 1 nuclear staining, the average survival rate in patients was 60% for strong nuclear staining and 28% for weak nuclear staining. There was significant statistical difference between groups according to their degree of nuclear staining (p=0.017). When the patients were evaluated according to cytoplasmic staining with E2F transcription factor 1, the average overall survival rate of patients with positive E2F transcription factor 1 cytoplasmic staining was 48.0±4.6% versus 55.9±7.9% for patients without staining (p=0.408).Conclusion: The survival rates are higher in rectal cancer patients with strong immunohistochemical nuclear staining of E2F transcription factor 1.

🔖

Cite This Article

UZER, H., AKYILDIZ, H. Y., SÖZÜER, E., AKCAN, A. C., ÖZ, A. B. (2017). Prognostic value of E2F1 in rectal cancer. Turkish Journal of Surgery, Cilt: 33 - Sayı: 3, 180–184. https://ajindex.com/articles/376563

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Okyay P. Colorectal Cancer Epidemiology. Turkiye Klinikleri J Med Oncol 2013; 6: 1-5
  2. Siegel RL, Miller KD, Jemal A. CA. Cancer statistics Cancer J Clin 2015; 65: 5-29. [CrossRef] 3. Polager S, Ginsberg D. E2F - at the crossroads of life and death. Trends Cell Biol 2008; 18: 528-535. [CrossRef] 4. Bramis J, Zacharatos P, Papaconstantinou I, Kotsinas A, Sigala F, Korkolis DP, et al. E2F-1 transcription factor immunoexpression is inversely associated with tumor growth in colon adenocarcinomas. Anticancer Res, 2004; 24: 3041-3047
  3. Bell LA, Ryan KM. Life and death decisions by E2F-1. Cell Death Differ 2004; 11: 137-142. [CrossRef] 6. Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 1993; 365: 349-352. [CrossRef] 7. Helin K. Regulation of cell proliferation by the E2F transcription factors. Curr Opin Genet Dev 1998; 8: 28-35. [CrossRef] 8. Onda M, Nagai H, Yoshida A, Miyamoto S, Asaka S, Akaishi J, et al. Up-regulation of transcriptional factor E2F1 in papillary and anaplastic thyroid cancers. J Hum Genet 2004; 49: 312-318. [CrossRef] 9. Lee J, Park CK, Park JO, Lim T, Park YS, Lim HY, et al. Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy. Clin Cancer Res 2008; 14: 82-88. [CrossRef] 10. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 979-994
  4. Saiz AD, Olvera M, Rezk S, Florentine BA, McCourty A, Brynes RK. Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions. J Pathol 2002; 198: 157- 162. [CrossRef] 12. Gorgoulis VG, Zacharatos P, Mariatos G, Kotsinas A, Bouda M, Kletsas D, et al. Transcription factor E2F-1 acts as a growthpromoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol 2002; 198: 142-156. [CrossRef] 13. Sabah M, Cummins R, Leader M, Kay E. Altered expression of cell cycle regulatory proteins in gastrointestinal stromal tumors: markers with potential prognostic implications. Hum Pathol 2006; 37: 648-655. [CrossRef] 14. Liang YX1, Lu JM1, Mo RJ1, He HC1, Xie J1, Jiang FN, et al. E2F1 promotes tumor cell invasion and migration through regulating CD147 in prostate cancer. Int J Oncol. 2016; 48: 1650-1658. [CrossRef] 15. Rabbani F, Richon